COMBI-EU (NCT03944356) is a prospective, non-interventional study that aims to assess adjuvant dabrafenib and trametinib usage in clinical practice, the impact of AE management, and the usage of app-based documentation on treatment adherence.<h4>Methods</h4>Adults with complete surgical resection of stage III BRAF V600-mutant cutaneous melanoma were included. This evidence concerns the gene BRAF and cutaneous melanoma.